Inactive Instrument

All News Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Real-time Estimate Cboe Europe Other stock markets 04:24:50 2024-04-29 am EDT			5-day change	1st Jan Change
27.3 ^SEK	-83.28%		-5.78%	-38.73%

Apr. 18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma Q1 - Improved European launch support	Apr. 19	AQ
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024	Apr. 18
Hansa Biopharma interim report January-March 2024	Apr. 18	AQ
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue	Apr. 12	MT
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	Apr. 11	AQ
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	Apr. 02	CI
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	Apr. 02	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	Mar. 21	AQ
Hansa Biopharma Hires New CFO	Feb. 22	MT
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	Feb. 22	AQ
Hansa Biopharma AB Announces CFO Changes	Feb. 22	CI
Hansa Biopharma - Improved sales prospects	Feb. 05	AQ
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024	Feb. 02
Hansa Biopharma Year-end report January-December 2023	Feb. 02	AQ
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 02	CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 02	CI
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	Jan. 06	AQ
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	Jan. 06	CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

All News

Filters